Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations

被引:9
作者
Nieder, Carsten [1 ,2 ]
Pawinski, Adam [1 ]
Andratschke, Nicolaus H. [3 ]
机构
[1] Nordland Hosp, Dept Oncol & Palliat Med, POB 1480,Prinsensgate 164, N-8092 Bodo, Norway
[2] Univ Tromso, Fac Hlth Sci, Inst Clin Med, Tromso, Norway
[3] Univ Hosp Rostock, Dept Radiat Oncol, Rostock, Germany
来源
FRONTIERS IN ONCOLOGY | 2013年 / 3卷
关键词
chemoradiation; chemotherapy; citation; non-small cell lung cancer; radiotherapy; research evaluation;
D O I
10.3389/fonc.2013.00176
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The important role of combined chemoradiation for several groups of patients with non small cell lung cancer (NSCLC) is reflected by the large number of scientific articles published during the last 30 years. Different measures of impact and clinical relevance of published research are available, each with its own pros and cons. For this review, article citation rate was chosen. Highly cited articles were identified through systematic search of the citation database Scopus. Among the 100 most often cited articles, meta-analyses (n = 5) achieved a median of 203 citations, guidelines (n = 7) 97, phase Ill trials (n = 29) 168, phase II trials (n = 21) 135, phase I trials (n = 7) 88, and others combined 115.5 (p = 0.001). Numerous national and international cooperative groups and several single institutions were actively involved in performing often cited, high-impact trials, reflecting the fact that NSCLC is a world-wide challenge that requires research collaboration. Platinum-containing combinations have evolved into a standard of care, typically administered concurrently. The issue of radiotherapy fractionation and total dose has also been studied extensively, yet with less conclusive results. Differences in target volume definition have been addressed. However, it was not possible to test all theoretically possible combinations of radiotherapy regimens, drugs, and drug doses (lower radiosensitizing doses compared to higher systemically active doses). That is why current guidelines offer physicians a choice of different, presumably equivalent treatment alternatives. This review identifies open questions and strategies for further research.
引用
收藏
页数:6
相关论文
共 72 条
  • [11] ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
    Brunelli, A.
    Charloux, A.
    Bolliger, C. T.
    Rocco, G.
    Sculier, J-P.
    Varela, G.
    Licker, M.
    Ferguson, M. K.
    Faivre-Finn, C.
    Huber, R. M.
    Clini, E. M.
    Win, T.
    De Ruysscher, D.
    Goldman, L.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (01) : 17 - 41
  • [12] Brunese L, 2013, MED SCI MONITOR, V19, P95, DOI 1
  • [13] Phase 2 Study of High-Dose Proton Therapy With Concurrent Chemotherapy for Unresectable Stage III Nonsmall Cell Lung Cancer
    Chang, Joe Y.
    Komaki, Ritsuko
    Lu, Charles
    Wen, Hong Y.
    Allen, Pamela K.
    Tsao, Anne
    Gillin, Michael
    Mohan, Radhe
    Cox, James D.
    [J]. CANCER, 2011, 117 (20) : 4707 - 4713
  • [14] CyberKnife with tumor tracking: an effective treatment for high-risk surgical patients with stage I non-small cell lung cancer
    Chen, Viola J.
    Oermann, Eric
    Vandat, Saloomeh
    Rabin, Jennifer
    Suy, Simeng
    Yu, Xia
    Collins, Sean P.
    Subramaniam, Deepa
    Banovac, Filip
    Anderson, Eric
    Collins, Brian T.
    [J]. FRONTIERS IN ONCOLOGY, 2012, 2
  • [15] Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer
    Choi, NC
    Carey, RW
    Daly, W
    Mathisen, D
    Wain, J
    Wright, C
    Lynch, T
    Grossbard, M
    Grillo, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 712 - 722
  • [16] Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
    Curran, Walter J., Jr.
    Paulus, Rebecca
    Langer, Corey J.
    Komaki, Ritsuko
    Lee, Jin S.
    Hauser, Stephen
    Movsas, Benjamin
    Wasserman, Todd
    Rosenthal, Seth A.
    Gore, Elizabeth
    Machtay, Mitchell
    Sause, William
    Cox, James D.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (19) : 1452 - 1460
  • [17] Dittman RO, 1996, JNCI-J NATL CANCER I, V88, P1210, DOI DOI 10.1093/JNCI/88.17.1210
  • [18] Bibliometric Indicators: Quality Measurements of Scientific Publication
    Durieux, Valerie
    Gevenois, Pierre Alain
    [J]. RADIOLOGY, 2010, 255 (02) : 342 - 351
  • [19] Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer:: Mature results of a phase II trial
    Eberhardt, W
    Wilke, H
    Stamatis, G
    Stuschke, M
    Harstrick, A
    Menker, H
    Krause, B
    Müeller, MR
    Stahl, M
    Flasshove, M
    Budach, V
    Greschuchna, D
    Konietzko, N
    Sack, H
    Seeber, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 622 - 634
  • [20] Ettinger DS, 2010, J NATL COMPR CANC NE, V8, P771